162635-04-3 | Temsirolimus

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$74.00	$52.00
5mg	95%	in stock	$88.00	$62.00
25mg	95%	in stock	$219.00	$153.00
100mg	95%	in stock	$604.00	$423.00
250mg	95%	in stock	$1,004.00	$703.00

Description

• Catalog Number: AI68877
• Chemical Name: Temsirolimus
• CAS Number: 162635-04-3
• Molecular Formula: C56H87NO16
• Molecular Weight: 1030.2871
• MDL Number: MFCD00934421
• SMILES: COC1CC(CCC1OC(=O)C(CO)(CO)C)CC(C1OC(=O)C2CCCCN2C(=O)C(=O)C2(O)OC(CCC2C)CC(OC)C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)C1)C)C)O)OC)C)C)C)C

Computed Properties

• Complexity: 2010
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 15
• Defined Bond Stereocenter Count: 4
• Heavy Atom Count: 73
• Hydrogen Bond Acceptor Count: 16
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 11
• XLogP3: 5.6

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• A phase II trial of temsirolimus in second-line metastatic urothelial cancer.

  Medical oncology (Northwood, London, England) 20121201

• Phase II trial of temsirolimus in patients with metastatic breast cancer.

  Breast cancer research and treatment 20121101

• Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

  Cancer 20121015

• Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20121015

• Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.

  Investigational new drugs 20121001

• Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?

  International journal of urology : official journal of the Japanese Urological Association 20121001

• Novel agents in Hodgkin lymphoma.

  Current oncology reports 20121001

• Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120920

• Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

  International journal of pharmaceutics 20120915

• Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?

  Anti-cancer drugs 20120901

• Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

  Japanese journal of clinical oncology 20120901

• Temsirolimus: a safety and efficacy review.

  Expert opinion on drug safety 20120901

• Inhibition of mTOR in carcinoid tumors.

  Targeted oncology 20120901

• Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.

  Acta oncologica (Stockholm, Sweden) 20120901

• Emerging agents for the treatment of mantle cell lymphoma.

  Expert review of anticancer therapy 20120901

• Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

  The oncologist 20120801

• Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.

  Anticancer research 20120801

• Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

  Neoplasia (New York, N.Y.) 20120801

• Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C gene mutation.

  Science translational medicine 20120725

• Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery.

  Advanced materials (Deerfield Beach, Fla.) 20120717

• Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

  The Journal of biological chemistry 20120706

• Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.

  European journal of cancer (Oxford, England : 1990) 20120701

• A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

  Cancer chemotherapy and pharmacology 20120701

• Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.

  Medical oncology (Northwood, London, England) 20120601

• Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.

  Clinical and experimental nephrology 20120601

• Inhibition of mammalian target of rapamycin signaling by CCI-779 (temsirolimus) induces growth inhibition and cell cycle arrest in Cashmere goat fetal fibroblasts (Capra hircus).

  DNA and cell biology 20120601

• Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.

  Journal of cancer research and clinical oncology 20120601

• A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.

  Cancer chemotherapy and pharmacology 20120601

• The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.

  Endocrine-related cancer 20120601

• Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120601

• Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120601

• Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20120601

• [Renal carcinoma: point on treatment of brain metastasis].

  Bulletin du cancer 20120601

• Molecular characterization and functional analysis of Cashmere goat mammalian target of rapamycin.

  DNA and cell biology 20120501

• Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

  Biochemical pharmacology 20120501

• Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions.

  Annales pharmaceutiques francaises 20120501

• Brief report: a phase II 'window-of-opportunity' frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120501

• A phase I study of temsirolimus and metformin in advanced solid tumours.

  Investigational new drugs 20120401

• [Renal tolerance of targeted therapies].

  Bulletin du cancer 20120301

• mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.

  Current treatment options in oncology 20120301

• Molecular/genetic therapies in ovarian cancer: future opportunities and challenges.

  Clinical obstetrics and gynecology 20120301

• Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.

  Cell death & disease 20120301

• Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120215

• Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120210

• [PI3K-AKT-mTOR pathway and cancer].

  Bulletin du cancer 20120201

• mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.

  Endocrine-related cancer 20120201

• The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.

  European journal of cancer (Oxford, England : 1990) 20120201

• Targeted therapies for renal cell carcinoma: review of adverse event management strategies.

  Journal of the National Cancer Institute 20120118

• mTOR pathway inhibition in renal cell carcinoma.

  Urologic oncology 20120101

• An update on targeted therapy in metastatic renal cell carcinoma.

  Urologic oncology 20120101

• The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.

  Breast cancer research and treatment 20120101

• Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120101

• Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.

  Acta oncologica (Stockholm, Sweden) 20120101

• Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma.

  European journal of cancer (Oxford, England : 1990) 20120101

• Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107).

  British journal of haematology 20120101

• An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.

  Journal of biopharmaceutical statistics 20120101

• Targeting mTOR pathways in human malignancies.

  Current pharmaceutical design 20120101

• Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.

  Dermatology (Basel, Switzerland) 20120101

• Reactivation of tuberculosis during temsirolimus therapy.

  Investigational new drugs 20111201

• Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors.

  Cancer letters 20111201

• Inhibition of induced autophagy increases apoptosis of Nara-H cells.

  International journal of oncology 20111201

• The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.

  Expert opinion on drug metabolism & toxicology 20111201

• [Antihormonal therapy in breast cancer and mTOR inhibitors].

  Bulletin du cancer 20111201

• Hydrogel containing L-valine residues as a platform for cisplatin chemotherapy.

  Colloids and surfaces. B, Biointerfaces 20111101

• Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.

  The Journal of pharmacology and experimental therapeutics 20111101

• A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111101

• Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice.

  Pain 20111101

• Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.

  International journal of clinical oncology 20111001

• Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.

  Anti-cancer drugs 20111001

• Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

  Gynecologic oncology 20111001

• Erythematous patches and plaques on the chest with induration of the breasts. Metastatic papillary RCC in dermal lymphatics.

  Archives of dermatology 20111001

• Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

• Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110910

• [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].

  Der Urologe. Ausg. A 20110901

• Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.

  Acta dermato-venereologica 20110901

• Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110901

• Renal carcinoma with (6;11)(p21;q12) translocation: report of an adult case.

  Pathology international 20110901

• Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820

• A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

  Cancer 20110801

• The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice.

  The American journal of pathology 20110801

• mTOR inhibitors in advanced renal cell carcinoma.

  Hematology/oncology clinics of North America 20110801

• [Adverse effects of new oncologic therapies].

  Praxis 20110727

• Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110720

• CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.

  Cancer research 20110715

• Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701

• Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.

  Cancer science 20110701

• Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

  The Lancet. Oncology 20110701

• Combination therapy in metastatic renal cell carcinoma.

  The Lancet. Oncology 20110701

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20110701

• Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.

  Anti-cancer drugs 20110601

• [Collecting duct renal cell carcinoma].

  Actas urologicas espanolas 20110601

• Treatment of metastatic renal cell carcinoma and renal pelvic cancer.

  Clinical and experimental nephrology 20110601

• Chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features.

  Journal of the American Academy of Dermatology 20110601

• Common toxicities of mammalian target of rapamycin inhibitors.

  Targeted oncology 20110601

• Temsirolimus in relapsed and/or refractory mantle cell lymphoma†: profile report.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110601

• Everolimus- and temsirolimus-associated enteritis: report of three cases.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110510

• Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501

• The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

  Oral oncology 20110501

• Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110501

• Efficacy and comparative effectiveness of sirolimus as an anticancer drug.

  The Laryngoscope 20110501

• Isolation and structure of homotemsirolimuses A, B, and C.

  Journal of natural products 20110425

• [Novelties in the treatment for advanced renal-cell cancer].

  Orvosi hetilap 20110424

• Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110420

• Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.

  Experimental hematology 20110401

• The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.

  The Journal of clinical endocrinology and metabolism 20110401

• Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

  The Lancet. Oncology 20110401

• New combinations for mantle cell lymphoma: concerted action needed.

  The Lancet. Oncology 20110401

• [Treatment of metastatic renal cell carcinoma].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20110401

• mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.

  Oncology reports 20110301

• Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

  The Lancet. Oncology 20110301

• Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

  Targeted oncology 20110301

• [Current status in molecular-targeted therapy and IFNα for renal cell carcinoma in Japan].

  Hinyokika kiyo. Acta urologica Japonica 20110301

• Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.

  British journal of cancer 20110215

• Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?

  Annals of oncology : official journal of the European Society for Medical Oncology 20110201

• Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.

  The oncologist 20110201

• Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.

  The oncologist 20110201

• Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

  The oncologist 20110201

• Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma.

  Annals of hematology 20110101

• Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110101

• Initial experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for metastatic renal cell cancer: good clinical response.

  Urologia internationalis 20110101

• Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.

  PloS one 20110101

• Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.

  Anticancer research 20110101

• Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.

  Journal of medical economics 20110101

• [Breast cancer therapy with combination of endocrine and target drugs].

  Voprosy onkologii 20110101

• Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

  Oncology 20110101

• Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.

  Dermatology (Basel, Switzerland) 20110101

• A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.

  PloS one 20110101

• S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.

  PloS one 20110101

• Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways.

  Blood 20101223

• Temsirolimus for metastatic desmoplastic small round cell tumor.

  Pediatric blood & cancer 20101215

• Mammalian target of rapamycin: biological function and target for novel anticancer agents.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101215

• BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.

  International journal of cancer 20101215

• Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.

  Head & neck 20101201

• Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat.

  The journal of pain : official journal of the American Pain Society 20101201

• Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

  European urology 20101201

• mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20101201

• More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.

  Anticancer research 20101201

• Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy.

  Prescrire international 20101201

• Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101115

• Concurrent involved field radiation therapy and temsirolimus in refractory mantle cell lymphoma (MCL).

  American journal of hematology 20101101

• Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101101

• Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction.

  Molecular cancer therapeutics 20101101

• Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.

  Expert opinion on biological therapy 20101101

• The therapy of kidney cancer with biomolecular drugs.

  Cancer treatment reviews 20101101

• Descending serotonergic facilitation mediated by spinal 5-HT3 receptors engages spinal rapamycin-sensitive pathways in the rat.

  Neuroscience letters 20101029

• Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.

  Drugs 20101001

• Combination therapy in patients with metastatic renal cell carcinoma.

  Clinical advances in hematology & oncology : H&O 20101001

• Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.

  Medical oncology (Northwood, London, England) 20100901

• Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer.

  Journal of molecular medicine (Berlin, Germany) 20100901

• Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

• Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.

  European urology 20100801

• A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

  Japanese journal of clinical oncology 20100801

• [Current impact of natural products in the discovery of anticancer drugs].

  Annales pharmaceutiques francaises 20100701

• Temsirolimus: is improved survival the correct expression of drug activity?

  The oncologist 20100701

• Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

  Medical oncology (Northwood, London, England) 20100601

• Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

  Investigational new drugs 20100601

• A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

  Gynecologic oncology 20100601

• Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.

  Anti-cancer drugs 20100601

• Treatment of metastatic renal cell carcinoma.

  Nature reviews. Urology 20100601

• [mTOR inhibitors].

  Nihon rinsho. Japanese journal of clinical medicine 20100601

• Smooth muscle cells orchestrate the endothelial cell response to flow and injury.

  Circulation 20100525

• Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.

  British journal of cancer 20100511

• Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100501

• Natural products in structure-assisted design of molecular cancer therapeutics.

  Current pharmaceutical design 20100501

• Papillary renal cell carcinoma with cutaneous metastases.

  The American journal of the medical sciences 20100501

• Long-interval T2-weighted subtraction magnetic resonance imaging: a powerful new outcome measure in multiple sclerosis trials.

  Annals of neurology 20100501

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20100501

• FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

  The oncologist 20100401

• Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.

  Journal of chemotherapy (Florence, Italy) 20100401

• [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].

  Aktuelle Urologie 20100301

• Sirolimus and temsirolimus for epithelioid angiomyolipoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100210

• Broadening the therapeutic scope for rapamycin treatment.

  Autophagy 20100201

• [Treatment of locally advanced renal tumors].

  Actas urologicas espanolas 20100201

• Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

  Cancer research 20100115

• Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.

  Liver international : official journal of the International Association for the Study of the Liver 20100101

• Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100101

• Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.

  Brain : a journal of neurology 20100101

• Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100101

• Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

• Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.

  Cancer research 20100101

• Temsirolimus.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Progress in the management of advanced renal cell carcinoma (RCC).

  Aktuelle Urologie 20100101

• [First-line therapy of metastatic renal cell carcinoma--update 2009].

  Onkologie 20100101

• [Outlook: Future therapy of renal cell carcinoma].

  Onkologie 20100101

• New therapeutic strategies for renal cell carcinoma.

  Urologic nursing 20100101

• [Renal cell carcinoma management and therapies in 2010].

  Bulletin du cancer 20100101

• [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].

  Bulletin du cancer 20100101

• [Targeted therapies: sequential and combined treatments].

  Bulletin du cancer 20100101

• [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].

  Bulletin du cancer 20100101

• [Advanced renal carcinomas with special situations. How to treat them?].

  Bulletin du cancer 20100101

• Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma.

  PharmacoEconomics 20100101

• Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

  BMC cancer 20100101

• Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.

  Journal of hematology & oncology 20100101

• The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice.

  Cellular immunology 20100101

• Targeted therapy in lymphoma.

  Journal of hematology & oncology 20100101

• Perspectives in the development of novel treatment approaches.

  Tumori 20100101

• Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.

  Cancer treatment reviews 20091201

• Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.

  Leukemia & lymphoma 20091201

• Metastatic renal cell carcinoma: current standards of care.

  Clinical journal of oncology nursing 20091201

• Management of mTOR inhibitor side effects.

  Clinical journal of oncology nursing 20091201

• Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.

  Seminars in oncology 20091201

• Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.

  Seminars in oncology 20091201

• Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

  Seminars in oncology 20091201

• Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.

  Seminars in oncology 20091201

• Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

  Seminars in oncology 20091201

• Temsirolimus for the treatment of mantle cell lymphoma.

  Expert review of hematology 20091201

• Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.

  Leukemia research 20091101

• Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20091101

• Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.

  Journal of dermatological science 20091101

• [Antitumoral effect of proliferation signal inhibitors].

  Gastroenterologie clinique et biologique 20091101

• Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents.

  Current hematologic malignancy reports 20091001

• Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

  Cancer research 20090915

• Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090915

• Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.

  Current opinion in supportive and palliative care 20090901

• Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090901

• [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090901

• Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.

  Cancer 20090815

• Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.

  Cancer 20090815

• Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810

• Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.

  Molecular cancer therapeutics 20090801

• Eosinophilic rash secondary to temsirolimus.

  Clinical genitourinary cancer 20090801

• Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.

  Clinical therapeutics 20090801

• Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.

  Cancer chemotherapy and pharmacology 20090701

• Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.

  BJU international 20090701

• (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20090701

• [The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].

  Zhonghua nan ke xue = National journal of andrology 20090701

• [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090601

• Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation.

  Anticancer research 20090601

• The role of antiangiogenesis therapy: bevacizumab and beyond.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090601

• Targeting mTOR in renal cell carcinoma.

  Cancer 20090515

• Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.

  Cancer chemotherapy and pharmacology 20090501

• Ready for a comeback of natural products in oncology.

  Biochemical pharmacology 20090501

• Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

  Cancer treatment reviews 20090501

• Tolerability of first-line therapy for metastatic renal cell carcinoma.

  Cancer treatment reviews 20090501

• Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.

  International journal of urology : official journal of the Japanese Urological Association 20090501

• [Targeted therapies and their indications in solid neoplasias].

  La Revue de medecine interne 20090501

• Targeted therapies in metastatic renal cancer in 2009.

  BJU international 20090501

• Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.

  The oncologist 20090501

• The applicability of mTOR inhibition in solid tumors.

  Current cancer drug targets 20090501

• The pharmacology of mTOR inhibition.

  Science signaling 20090421

• Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.

  Clinical journal of oncology nursing 20090401

• Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.

  Cancer chemotherapy and pharmacology 20090301

• Recent advances in the systemic treatment of metastatic papillary renal cancer.

  Expert review of anticancer therapy 20090301

• AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Temsirolimus in patients with advanced renal cell carcinoma: an overview.

  Advances in therapy 20090101

• Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.

  BMC cancer 20090101

• [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

  Aktuelle Urologie 20090101

• [Topics in mTOR pathway and its inhibitors].

  Bulletin du cancer 20090101

• Temsirolimus-induced glomerulopathy.

  Oncology 20090101

• Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.

  Clinical genitourinary cancer 20090101

• Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies.

  Medical oncology (Northwood, London, England) 20090101

• New therapeutic approaches in the management of metastatic renal cell carcinoma.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20090101

• [Acute renal failure in a patient with renal carcinoma treated with temsirolimus].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

• Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.

  Breast cancer research : BCR 20090101

• Exploring the role of novel agents in the treatment of renal cell carcinoma.

  Cancer treatment reviews 20081201

• Temsirolimus in patients with renal cancer on hemodialysis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201

• Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.

  Cancer biology & therapy 20081201

• Temsirolimus in renal cell carcinoma.

  Transplantation proceedings 20081201

• Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.

  Prescrire international 20081201

• [Molecular basis of targeted therapy in metastatic renal cancer].

  Der Pathologe 20081101

• Mechanism of action of rapalogues: the antiangiogenic hypothesis.

  Expert opinion on investigational drugs 20081101

• Systemic therapy for metastatic renal cell carcinoma.

  The Urologic clinics of North America 20081101

• mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

  British journal of cancer 20081021

• [Value of targeted therapies for renal cell cancer].

  Der Urologe. Ausg. A 20081001

• Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

  Nature clinical practice. Oncology 20081001

• Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20081001

• [Targeted therapy - point blank or single shot].

  Der Urologe. Ausg. A 20081001

• Novel drugs for renal cell carcinoma.

  Expert opinion on investigational drugs 20081001

• [Systemic therapy of metastasizing renal cell carcinoma].

  Der Urologe. Ausg. A 20081001

• Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

  European journal of cancer (Oxford, England : 1990) 20081001

• [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

  The oncologist 20081001

• Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins.

  European journal of pharmacology 20080904

• Targeted therapy in renal cell carcinoma.

  Current opinion in urology 20080901

• Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.

  Reviews on recent clinical trials 20080901

• [Renal cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• NCCN Task Force Report: mTOR inhibition in solid tumors.

  Journal of the National Comprehensive Cancer Network : JNCCN 20080901

• Watchdog set to reject four drugs for kidney cancer on the NHS.

  BMJ (Clinical research ed.) 20080814

• Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Temsirolimus in metastatic renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080801

• Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.

  Cancer 20080801

• Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

  Clinical journal of oncology nursing 20080801

• Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.

  Journal of hepatology 20080701

• New drugs08, part 2.

  Nursing 20080701

• Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.

  Oncology nursing forum 20080701

• Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

  British journal of cancer 20080603

• Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.

  Molecular cancer therapeutics 20080601

• [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080601

• Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

  European urology 20080501

• Renal cell carcinoma.

  Current opinion in oncology 20080501

• Molecular target therapies in endometrial cancer: from the basic research to the clinic.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20080501

• A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.

  Cancer research 20080415

• [Renal cell carcinoma and antiangiogenic therapies].

  Presse medicale (Paris, France : 1983) 20080401

• Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.

  Experimental hematology 20080401

• Treatment options for metastatic renal cell carcinoma: a review.

  The Canadian journal of urology 20080401

• Drug essentials mTOR inhibitors.

  Oncology (Williston Park, N.Y.) 20080401

• Temsirolimus, an inhibitor of mammalian target of rapamycin.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

  Nederlands tijdschrift voor geneeskunde 20080216

• Pulmonary complications of novel antineoplastic agents for solid tumors.

  Chest 20080201

• The potential role of mTOR inhibitors in non-small cell lung cancer.

  The oncologist 20080201

• [Molecular targeted therapy for renal cell carcinoma].

  Hinyokika kiyo. Acta urologica Japonica 20080101

• Pathobiology and prognosis of chromophobe renal cell carcinoma.

  Urologic oncology 20080101

• Temsirolimus: in advanced renal cell carcinoma.

  Drugs 20080101

• An update on the medical therapy of advanced metastatic renal cell carcinoma.

  Scandinavian journal of urology and nephrology 20080101

• IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth.

  Anticancer research 20080101

• Signaling inhibitors in metastatic renal cell carcinoma.

  Cancer journal (Sudbury, Mass.) 20080101

• Targeted drugs for metastatic renal cell carcinoma.

  Lancet (London, England) 20071222

• Temsirolimus (Torisel) for advanced renal cell carcinoma.

  The Medical letter on drugs and therapeutics 20071217

• Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071215

• [mTOR signal pathway and its inhibitors in antitumor therapy: a review].

  Ai zheng = Aizheng = Chinese journal of cancer 20071201

• Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications.

  Journal of clinical pharmacology 20071101

• A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20071101

• Temsirolimus for advanced renal cell carcinoma.

  Clinical advances in hematology & oncology : H&O 20071101

• Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.

  The Journal of investigative dermatology 20071001

• Rapamycin: something old, something new, sometimes borrowed and now renewed.

  Clinical pharmacology and therapeutics 20071001

• Temsirolimus.

  Drugs of today (Barcelona, Spain : 1998) 20071001

• Temsirolimus for advanced renal-cell carcinoma.

  The New England journal of medicine 20070906

• Temsirolimus for advanced renal-cell carcinoma.

  The New England journal of medicine 20070906

• In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Treatment options in renal cell carcinoma: past, present and future.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070901

• Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901

• Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.

  Clinical genitourinary cancer 20070901

• Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

  Clinical genitourinary cancer 20070901

• American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.

  IDrugs : the investigational drugs journal 20070801

• The biology behind mTOR inhibition in sarcoma.

  The oncologist 20070801

• Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.

  Expert review of anticancer therapy 20070801

• The role of mTOR inhibitors for treatment of sarcomas.

  Current oncology reports 20070701

• Temsirolimus in the treatment of advanced renal cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070701

• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  The New England journal of medicine 20070531

• Do the results of the new trials change the standard treatment of metastatic renal cell cancer?

  Onkologie 20070501

• Clinical development of mTOR inhibitors: a focus on lymphoma.

  Reviews on recent clinical trials 20070501

• Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

  Blood 20070415

• AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells.

  Oncogene 20070405

• Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.

  British journal of cancer 20070326

• Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.

  Cancer research 20070301

• Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.

  Cancer treatment reviews 20070201

• Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.

  Molecular cancer therapeutics 20070201

• Evaluating the activity of temsirolimus in neuroendocrine cancer.

  British journal of cancer 20070115

• New therapeutics for soft-tissue sarcomas in adults.

  Oncology (Williston Park, N.Y.) 20070101

• Newly approved therapies for RCC and their effect on the standard of care.

  Clinical advances in hematology & oncology : H&O 20070101

• CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

  Pharmacology 20070101

• Advanced renal cell carcinoma: current and emerging management strategies.

  Drugs 20070101

• The role of targeted therapy in metastatic renal cell carcinoma.

  TheScientificWorldJournal 20070101

• [Effect of angiogenesis inhibitors on renal cell carcinoma].

  Magyar onkologia 20070101

• New drugs: ambrisentan, temsirolimus, and eculizumab.

  Journal of the American Pharmacists Association : JAPhA 20070101

• Molecule of the month. Temsirolimus.

  Drug news & perspectives 20070101

• [Angiogenesis targeting in renal carcinomas].

  Bulletin du cancer 20070101

• Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.

  BMC pharmacology 20070101

• Targeting von Hippel-Lindau pathway in renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061215

• Targeted therapy for metastatic renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061210

• Molecularly targeted therapy in renal cell carcinoma: where do we go from here?

  Expert review of anticancer therapy 20061201

• Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.

  Expert review of anticancer therapy 20061201

• A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

  British journal of cancer 20061106

• [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].

  Bulletin du cancer 20061101

• Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.

  Genes, chromosomes & cancer 20061001

• A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• Molecular biology of renal cell carcinoma.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001

• Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.

  Clinical breast cancer 20061001

• Three new drugs available to fight kidney cancer.

  Journal of the National Cancer Institute 20060906

• New treatment approaches in metastatic renal cell carcinoma.

  Current opinion in urology 20060901

• Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus.

  Endocrine-related cancer 20060901

• Therapeutic targets: MTOR and related pathways.

  Cancer biology & therapy 20060901

• Current status of clinical trials for glioblastoma.

  Reviews on recent clinical trials 20060901

• Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.

  European journal of cancer (Oxford, England : 1990) 20060801

• An in vivo platform for translational drug development in pancreatic cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060801

• New hope for RCC patients.

  European journal of cancer (Oxford, England : 1990) 20060801

• Trials probe new agents for kidney cancer.

  JAMA 20060712

• Mammalian target of rapamycin inhibitors in sarcomas.

  Current opinion in oncology 20060701

• Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.

  Anti-cancer drugs 20060601

• Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

  Cancer research 20060601

• Perspectives in central nervous system malignancies.

  IDrugs : the investigational drugs journal 20060601

• Targeting mTOR for cancer treatment.

  Current opinion in investigational drugs (London, England : 2000) 20060601

• New therapies in the treatment of breast cancer.

  Seminars in oncology 20060601

• Molecular targeting therapy for renal cell carcinoma.

  International journal of clinical oncology 20060601

• In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.

  International journal of cancer 20060501

• Autophagy: A protective mechanism in response to stress and inflammation.

  Current opinion in investigational drugs (London, England : 2000) 20060501

• CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.

  Neoplasia (New York, N.Y.) 20060501

• Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

  Cancer research 20060215

• The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.

  Blood 20060201

• mTOR and cancer: reason for dancing at the crossroads?

  Current opinion in genetics & development 20060201

• [Progress in therapeutic strategy for renal cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060201

• mTOR inhibitors.

  Clinical advances in hematology & oncology : H&O 20060101

• Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101

• PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.

  Biochemical and biophysical research communications 20051104

• Mammalian target of rapamycin as a therapeutic target in leukemia.

  Current molecular medicine 20051101

• Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

  Molecular cancer therapeutics 20051001

• Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.

  Clinical breast cancer 20051001

• CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

  Cancer 20050901

• lipase-catalyzed regioselective esterification of rapamycin: synthesis of temsirolimus (CCI-779).

  Organic letters 20050901

• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810

• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810

• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810

• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

  Investigational new drugs 20050801

• Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition.

  Hepatology (Baltimore, Md.) 20050601

• [Experimental study of Mytrolimus-eluting stents on preventing restenosis in porcine coronary model].

  Zhonghua xin xue guan bing za zhi 20050601

• The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.

  Biochemical and biophysical research communications 20050527

• Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

  Cancer research 20050415

• Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.

  Cancer research 20050401

• mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.

  Neoplasia (New York, N.Y.) 20050401

• Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.

  Cancer research 20050315

• Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

  Genes, chromosomes & cancer 20050301

• Scientists hopeful as they uncover molecular clues to prostate cancer.

  Journal of the National Cancer Institute 20050202

• Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050201

• Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer.

  Clinical pharmacology and therapeutics 20050101

• Inhibition of different intracellular signal cascades in human pancreatic cancer cells.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20050101

• Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.

  Molecular cancer 20050101

• In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

  Blood 20041215

• Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• [16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics].

  Bulletin du cancer 20041201

• Mammalian target of rapamycin.

  Seminars in oncology 20041201

• Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

  Investigational new drugs 20041101

• Combining targeted agents in lung cancer.

  Clinical lung cancer 20041101

• New target, new drug, old paradigm.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615

• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040615

• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

• Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.

  Cancer 20040215

• Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor.

  The Journal of urology 20040201

• AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression.

  The Journal of biological chemistry 20040123

• Overcoming endocrine therapy resistance by signal transduction inhibition.

  The oncologist 20040101

• New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.

  Breast cancer research : BCR 20040101

• Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779.

  Drugs in R&D 20040101

• New therapeutic strategies for soft tissue sarcomas.

  Current treatment options in oncology 20031201

• Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030601

• Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030101

• Synthetic lethality: killing cancer with cancer.

  Journal of the National Cancer Institute 20021120

• Clinical development of mammalian target of rapamycin inhibitors.

  Hematology/oncology clinics of North America 20021001

• Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.

  Cancer research 20020901

• Goosebumps.

  Lancet (London, England) 20020831

• CCI-779 Wyeth.

  Current opinion in investigational drugs (London, England : 2000) 20020801

• Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

  Current opinion in investigational drugs (London, England : 2000) 20020201

• Rapamycin's resurrection: a new way to target the cancer cell cycle.

  Journal of the National Cancer Institute 20011017

• mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

  Endocrine-related cancer 20010901

• Advances in systemic therapy of small cell cancer of the lung.

  Expert review of anticancer therapy 20010801

• Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010601

• Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

  Cancer research 20010215